The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians
Abstract
Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Qaseem, A., Snow, V., Owens, D. K., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00010 · Cited by 233
Self-citationJohnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01448.x · Cited by 161
Research works printed but not linked: 121
- 10.7326/0003-4819-156-3-201202070-00011 · DOI · Paper page
- 10.1007/s00125-010-1906-6 · DOI
- 10.1093/eurheartj/ehr077 · DOI · Paper page
- 10.1007/s00125-013-2958-1 · DOI
- 10.1111/j.1463-1326.2012.01604.x · DOI
- 10.1007/s00228-010-0939-6 · DOI
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2, 1031
- 10.1016/j.metabol.2009.03.007 · DOI
- 10.1016/j.diabres.2008.07.021 · DOI
- 10.1055/s-0034-1370989 · doi:10.1055/s-0034-1370989
- 10.1111/j.1463-1326.2011.01367.x · DOI
- 10.1055/s-0034-1396864 · DOI
- 10.1111/jdi.12157 · DOI
- 10.1007/s00592-011-0276-y · DOI
- 10.1007/s12325-013-0003-x · DOI
- 10.1111/j.1463-1326.2008.00965.x · DOI
- 10.2337/diabetes.51.12.3479 · DOI · Paper page
- Iliadis F, 2007, In Vivo, 21, 1107
- 10.1055/s-0029-1202792 · DOI
- 10.1016/j.diabres.2009.07.004 · DOI
- 10.2337/diacare.27.1.41 · DOI
- 10.1210/jc.2002-021786 · DOI · Paper page
- 10.1185/03007990903350011 · DOI
- Ramachandran A, 2004, J Assoc Physicians India, 52, 459
- 10.1111/j.1463-1326.2006.00659.x · DOI
- 10.2337/dc11-1107 · DOI · Paper page
- 10.1210/jc.2003-030861 · DOI · Paper page
- 10.1016/j.peptides.2012.12.020 · DOI
- 10.1111/j.1464-5491.2005.01656.x · DOI
- 10.4093/dmj.2011.35.1.26 · DOI
- 10.5551/jat.14.86 · DOI
- 10.1016/j.numecd.2005.12.003 · DOI
- 10.1592/phco.26.10.1388 · DOI
- 10.1016/j.metabol.2004.05.013 · DOI
- 10.1016/S1056-8727(00)00124-0 · DOI
- 10.1038/sj.jhh.1001444 · DOI · Paper page
- 10.1016/j.jacc.2005.03.041 · DOI · Paper page
- 10.1016/S0149-2918(04)90068-9 · DOI
- 10.1111/j.1464-5491.2004.01258.x · DOI
- 10.1002/dmrr.633 · DOI
- 10.1111/j.2040-1124.2011.00115.x · DOI
- 10.1185/03007990802705679 · DOI
- 10.1111/j.1463-1326.2009.01187.x · DOI
- 10.1111/j.1463-1326.2009.01056.x · DOI · Paper page
- 10.1111/dom.12258 · DOI
- 10.1111/j.1463-1326.2010.01204.x · DOI
- 10.1111/j.1463-1326.2012.01590.x · DOI
- 10.1111/j.1463-1326.2011.01385.x · DOI
- 10.1111/dom.12011 · DOI
- 10.1053/j.ajkd.2012.11.043 · DOI
- 10.1111/j.1463-1326.2007.00839.x · DOI · Paper page
- 10.1111/j.1742-1241.2012.02911.x · DOI · Paper page
- 10.2337/dc13-0663 · DOI · Paper page
- 10.1111/dom.12185 · DOI · Paper page
- 10.2337/dc11-1926 · DOI · Paper page
- 10.1007/s00125-013-3039-1 · DOI · Paper page
- 10.2337/dc14-1142 · DOI · Paper page
- 10.1111/dom.12459 · DOI · Paper page
- 10.1016/S0140-6736(13)60683-2 · DOI · Paper page
- 10.2337/dc11-0606 · DOI · Paper page
- 10.1016/S2213-8587(14)70120-2 · DOI · Paper page
- 10.2337/dc13-2762 · DOI · Paper page
- 10.4158/EP09146.OR · DOI
- 10.4103/0976-500X.107656 · DOI
- 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
- 10.1210/jc.2011-2243 · DOI
- 10.1111/j.1464-5491.2007.02160.x · DOI
- 10.1097/01.hjh.0000244955.39491.88 · DOI
- 10.1185/030079906X104786 · DOI
- 10.1592/phco.25.5.637.63587 · DOI
- 10.1111/j.1463-1326.2005.00570.x · DOI
- 10.1097/MEG.0b013e3283608317 · DOI
- 10.1007/s00508-009-1279-3 · DOI
- 10.1055/s-2007-984441 · DOI
- 10.1016/S2213-8587(13)70084-6 · DOI · Paper page
- 10.2337/dc10-0159 · DOI
- 10.2337/diacare.25.11.2058 · DOI · Paper page
- 10.1185/03007990902820816 · DOI
- 10.1001/jama.283.13.1695 · DOI · Paper page
- 10.1016/j.diabres.2004.09.002 · DOI
- 10.1210/jc.2002-021225 · DOI
- 10.1016/S0149-2918(03)80112-1 · DOI
- 10.1046/j.1464-5491.2002.00774.x · DOI
- 10.1046/j.1463-1326.2002.00211.x · DOI
- 10.2337/diacare.17.10.1100 · DOI · Paper page
- Hermann LS, 1991, Diabete Metab, 17, 201
- 10.1046/j.1464-5491.2001.00582.x · DOI
- 10.1111/j.1464-5491.2010.03131.x · DOI
- 10.1007/s13300-012-0013-8 · DOI
- 10.1111/j.1463-1326.2011.01390.x · DOI
- 10.1016/j.diabres.2011.07.035 · DOI
- 10.1111/j.1753-0407.2012.00213.x · DOI
- 10.2169/internalmedicine.52.8175 · DOI
- 10.1186/1472-6823-14-17 · DOI
- 10.1185/03007995.2012.714360 · DOI
- 10.1111/j.1742-1241.2008.01933.x · DOI · Paper page
- 10.1111/j.1463-1326.2010.01326.x · DOI · Paper page
- 10.1111/j.1463-1326.2012.01620.x · DOI
- 10.1111/1753-0407.12284 · DOI
- Qiu R, 2014, J Clin Transl Endocrinol, 1, 54
- 10.2337/dc13-2105 · DOI · Paper page
- 10.1111/j.1463-1326.2010.01334.x · DOI · Paper page
- 10.1002/dmrr.2525 · DOI
- 10.1111/j.1463-1326.2006.00704.x · DOI · Paper page
- 10.1111/dom.12461 · DOI
- 10.1111/dom.12387 · DOI
- 10.1139/cjpp-2012-0300 · DOI
- 10.1111/j.1464-5491.2012.03589.x · DOI · Paper page
- 10.1046/j.1463-1326.2002.00229.x · DOI
- 10.1016/S1726-4901(08)70044-3 · DOI
- 10.1111/jdi.12201 · DOI
- 10.2337/dc14-0024 · DOI · Paper page
- Gupta A, 2013, Int J Pharm Sci Rev Res, 23, 137
- 10.1111/j.1742-1241.2010.02510.x · DOI · Paper page
- 10.1111/j.1742-1241.2010.02353.x · DOI · Paper page
- 10.1016/S0140-6736(12)60691-6 · DOI · Paper page
- 10.1111/dom.12377 · DOI
- 10.2165/11316510-000000000-00000 · DOI
- 10.1186/1741-7015-11-43 · DOI · Paper page
- 10.1111/dom.12189 · DOI · Paper page
- 10.1016/0197-2456(95)00134-4 · DOI · Paper page
Cited by
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Qaseem, A., Wilt, T. J., Kansagara, D., Horwitch, C., Barry, M. J., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2018) · Annals of Internal Medicine · doi:10.7326/m17-0939 · Cited by 412
Self-citationPotential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas Jr., C., Mosa, R. A., Viegas, F. P., & Pooe, O. J. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 321
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Metadata
- Authors
- Qaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-02-21
- Volume
- 166
- Issue
- 4
- Pages
- 279-290
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4233007762
- Cited by
- 207
- References
- 12
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. https://app.cochat.ai/papers/10.7326/m16-1860
- The paper
- Qaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians*. (2017). Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Annals of Internal Medicine. https://doi.org/10.7326/m16-1860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.